High Blood BAALC Copy Numbers Determined By Digital Droplet PCR at Timepoint of Allogeneic Transplantation in Complete Remission Predicts Relapse in Patients with Acute Myeloid Leukemia
نویسندگان
چکیده
منابع مشابه
High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients
High BAALC expression levels at acute myeloid leukemia diagnosis have been linked to adverse outcomes. Recent data indicate that high BAALC expression levels may also be used as marker for residual disease following acute myeloid leukemia treatment. Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative treatment for acute myeloid leukemia patients. However, disease recurre...
متن کاملfirst complete remission versus other- than- first complete remission in acute myelogenous leukemia with allogeneic hematopoietic stem cell transplantation
introduction: the traditional goal of the treatment of acute myelogenous leukemia is to produce and maintain a complete remission (cr).the difference in survival time was entirely attributable to the duration of time spent in cr .in this study, the outcome of aml patients with allogeneic hsct in cr1 versus other than cr1 was compared. patients and methods: since march 1991 until november 2008, ...
متن کاملEffect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia.
Several studies have shown that allogeneic hematopoietic cell transplantation (HCT) in first complete remission (CR1) of AML reduces the risk of relapse and improves relapse-free survival in intermediateand poor-risk AML. Benefits in (overall) survival are less obvious. One possible explanation is that following the occurrence of relapse, previous receipt of allogeneic HCT in CR1 is associated ...
متن کاملAllogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.
Allogeneic hematopoietic cell transplantation (HCT) is the most potent therapy for preventing relapse of acute myeloid leukemia (AML). Although its efficacy is compromised by a high risk of treatment-related morbidity and mortality, an accumulating body of evidence has led to the general recommendation favoring allogeneic HCT from a matched sibling donor during first complete remission (CR1) fo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2016
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v128.22.517.517